Milestone Pharmaceuticals Inc. (MIST)
NASDAQ: MIST · Real-Time Price · USD
1.110
-0.090 (-7.50%)
At close: May 9, 2025, 4:00 PM
1.140
+0.030 (2.70%)
After-hours: May 9, 2025, 7:47 PM EDT
Milestone Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
33
Market Cap
73.55M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
MIST News
- 5 weeks ago - Stock Picks From Seeking Alpha's March 2025 New Analysts - Seeking Alpha
- 6 weeks ago - Milestone Pharmaceuticals Shares Hit New Low After FDA Rejects Etripamil - Market Watch
- 6 weeks ago - US FDA declines to approve Milestone Pharma's heart rhythm nasal spray - Reuters
- 6 weeks ago - FDA Issues Complete Response Letter for Etripamil for PSVT - GlobeNewsWire
- 7 weeks ago - Milestone Pharmaceuticals: A Compelling Value Proposition For Patients And Payers - Seeking Alpha
- 7 weeks ago - Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology - GlobeNewsWire
- 2 months ago - Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update - GlobeNewsWire
- 2 months ago - Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire